Arcus Biosciences Stock Forecast, Price & News

Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions

Is Arcus Biosciences a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Arcus Biosciences stock.
View analyst ratings for Arcus Biosciences or view top-rated stocks.

What stocks does MarketBeat like better than Arcus Biosciences?

Wall Street analysts have given Arcus Biosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arcus Biosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Arcus Biosciences' next earnings date?

Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Arcus Biosciences.

How were Arcus Biosciences' earnings last quarter?

Arcus Biosciences, Inc. (NYSE:RCUS) issued its quarterly earnings data on Wednesday, August, 4th. The company reported ($1.09) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.87) by $0.22. The company had revenue of $9.46 million for the quarter, compared to analysts' expectations of $18.43 million. Arcus Biosciences had a negative trailing twelve-month return on equity of 34.30% and a negative net margin of 213.68%.
View Arcus Biosciences' earnings history.

How has Arcus Biosciences' stock been impacted by Coronavirus (COVID-19)?

Arcus Biosciences' stock was trading at $16.97 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RCUS shares have increased by 112.0% and is now trading at $35.97.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for RCUS?

8 Wall Street analysts have issued 12-month price targets for Arcus Biosciences' stock. Their forecasts range from $43.00 to $70.00. On average, they anticipate Arcus Biosciences' stock price to reach $55.50 in the next twelve months. This suggests a possible upside of 54.3% from the stock's current price.
View analysts' price targets for Arcus Biosciences or view top-rated stocks among Wall Street analysts.

Who are Arcus Biosciences' key executives?

Arcus Biosciences' management team includes the following people:

• Terry J. Rosen, Chairman & Chief Executive Officer
• Juan Carlos Jaen, President & Director
• Jennifer Jarrett, Chief Operating Officer & Director
• Robert C. Goeltz, Chief Financial & Accounting Officer
• Steve Young, Senior VP-Technology & Quantitative Biology

What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO?

4 employees have rated Arcus Biosciences CEO Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among Arcus Biosciences' employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Arcus Biosciences' key competitors?

Some companies that are related to Arcus Biosciences include Teva Pharmaceutical Industries (TEVA), Ascendis Pharma A/S (ASND), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Evotec (EVTCY), Mirati Therapeutics (MRTX), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Sarepta Therapeutics (SRPT), Legend Biotech (LEGN), Arrowhead Pharmaceuticals (ARWR), Ultragenyx Pharmaceutical (RARE), HUTCHMED (HCM), Blueprint Medicines (BPMC) and Allakos (ALLK).
View all of RCUS's competitors.

What other stocks do shareholders of Arcus Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD).

When did Arcus Biosciences IPO?

(RCUS) raised $99 million in an initial public offering (IPO) on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO.

What is Arcus Biosciences' stock symbol?

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Who are Arcus Biosciences' major shareholders?

Arcus Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.66%), FMR LLC (4.33%), BVF Inc. IL (3.92%), State Street Corp (3.76%), Vanguard Group Inc. (3.45%) and Woodline Partners LP (2.33%). Company insiders that own Arcus Biosciences stock include Carolyn C Tang, Gilead Sciences Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends for Arcus Biosciences.

Which major investors are selling Arcus Biosciences stock?

RCUS stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Balyasny Asset Management LLC, Goldman Sachs Group Inc., Invesco Ltd., Vanguard Group Inc., Citadel Advisors LLC, First Trust Advisors LP, and TimesSquare Capital Management LLC. Company insiders that have sold Arcus Biosciences company stock in the last year include Carolyn C Tang, Jennifer Jarrett, Juan C Jaen, Terry J Rosen, and William Grossman.
View insider buying and selling activity for Arcus Biosciences or view top insider-selling stocks.

Which major investors are buying Arcus Biosciences stock?

RCUS stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, FMR LLC, BlackRock Inc., State Street Corp, Woodline Partners LP, Octagon Capital Advisors LP, Nuveen Asset Management LLC, and Northern Trust Corp. Company insiders that have bought Arcus Biosciences stock in the last two years include Gilead Sciences Inc, Kathryn E Falberg, Robert C Goeltz II, William Grossman, and Yasunori Kaneko.
View insider buying and selling activity for Arcus Biosciences or or view top insider-buying stocks.

How do I buy shares of Arcus Biosciences?

Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Arcus Biosciences' stock price today?

One share of RCUS stock can currently be purchased for approximately $35.97.

How much money does Arcus Biosciences make?

Arcus Biosciences has a market capitalization of $2.57 billion and generates $77.52 million in revenue each year. The company earns $-122,860,000.00 in net income (profit) each year or ($2.24) on an earnings per share basis.

How many employees does Arcus Biosciences have?

Arcus Biosciences employs 236 workers across the globe.

What is Arcus Biosciences' official website?

The official website for Arcus Biosciences is www.arcusbio.com.

Where are Arcus Biosciences' headquarters?

Arcus Biosciences is headquartered at 3928 Point Eden Way, Hayward CA, 94545.

How can I contact Arcus Biosciences?

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at (510) 694-6200 or via email at [email protected].